Promising results booked

TuBerculosis Vaccine Initiative (TBVI) already has an outstanding track record. The TBVAC project (2004-2009) – the European Union funded project TBVI managed and evolved from – resulted in:
  • 4 new vaccine candidates in preclinical and non clinical stages
  • 4 new vaccine candidates in clinical phase I to II (testing safety and immunogenicity)
  • 15 candidate biomarkers (used to monitor the effectiveness of new vaccines) with the potential to be used in monitoring of clinical trials
  • 3 adjuvant molecules (used to enhance the immunogenicity and therefore the efficacy of vaccines), 1 of which is in clinical phase I studies.

The most advanced vaccine candidate is currently being tested for efficacy in a Phase IIb study. If successfully tested in further clinical stages this vaccine could hopefully be licensed by 2017.

The research continues in NEWTBVAC (2010-2014).

View our media centre »

TBVI has already made its mark. It has ensured that research and development for TB vaccines and biomarkers has taken a significant step forward.

John Bowis, former Member of European Parliament, former minister of Health UK